With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care

2.

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

3.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

4.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

5.

Non-Hodgkin lymphomas that are indolent have been linked to psychological distress.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot